AHA Hypertension 2025 Poster: Efficacy and Safety of Lorundrostat in Hypertension Patients With High Unmet Medical Need: Subgroup Analyses of the Launch-HTN Trial in[...]

Mineralys Therapeutics Inc. published this content on September 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 05, 2025 at 18:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]